^
Association details:
| Biomarker: | TNFRSF17 overexpression |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | Carvykti (ciltacabtagene autoleucel) (BCMA-targeted CAR-T immunotherapy) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)
Published date:
11/06/2019
Excerpt:
JNJ-4528 CAR+ cellular and transgene levels showed expansion and persistence in both blood and BM, with peak expansion 9-14 days after dosing in a majority of pts. All pts showed similar kinetics of decline in soluble BCMA (sBCMA) levels, and continued depletion in sBCMA suggests CAR-T mediated pharmacodynamic activity.
DOI:
https://doi.org/10.1182/blood-2019-121731
Trial ID:
